Lupin announced that its alliance partner has obtained two approvals from the US Food and Drug Administration (USFDA).
The USFDA has granted the final approval to Caplin Steriles, a partner of Lupin, to market its generic version of Zemuron Bromide Injection, 50 mg/5 ml and 100 mg/10 m,l produced by Organon USA Inc.
Caplin Steriles obtained this approval through its abbreviated new drug application (ANDA) for Rocuronium Bromide Injection, 10mg/ml, which will be available in 5 ml and 10 ml multi-dose vials.
In the United States, Rocuronium Bromide Injection recorded an annual sale of around $53 million.
Furthermore, Lupin’s partner Caplin Steriles has also received the final approval from the FDA for its Thiamine Hydrochloride Injection USP, 200 mg/2 ml (100 mg/ml) in multiple-dose vials.
This approval allows Caplin Steriles to introduce a therapeutically equivalent version of Fresenius Kabi USA LLC’s Thiamine Hydrochloride Injection USP, 200 mg/2 ml (100mg/ml).
In the United States, sales of Thiamine Hydrochloride Injection USP amounted to roughly $36 million on an annual basis.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.